Literature DB >> 10478322

Requirements for human chorionic gonadotropin and recombinant human luteinizing hormone for follicular development and maturation.

C Y Andersen1, S Ziebe, X Guoliang, A G Byskov.   

Abstract

PURPOSE: Our purpose was to evaluate the requirements for human chorionic gonadotropin (hCG) and recombinant luteinizing hormone (rec-LH) for follicular development and maturation in mice.
METHODS: We carried out ovarian stimulation of immature mice. Output parameters were the preembryos created in vivo and frequency of blastocyst formation in vitro.
RESULTS: hCG at 0 to 1 IU resulted in a dose-dependent recovery of preembryos (0 to 39.7 +/- 4.3; mean +/- SE) per mouse. hCG at 1 and 10 hCG gave similar results, whereas higher doses significantly reduced the number of preembryos. Potential for blastocyst formation was independent of hCG dose. hCG and rec-LH together exerted a synergistic effect on the recovery of preembryos.
CONCLUSIONS: Optimal follicular development required a combination of 20 IU follicle stimulating hormone and 1-10 IU hCG. The potency of hCG was higher than that of rec-LH, but a synergistic effect of rec-LH and hCG was observed. The results may be pertinent for the development of strategies for ovarian stimulation of women with low levels of endogenous LH.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10478322      PMCID: PMC3455491          DOI: 10.1023/a:1020569508927

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  18 in total

Review 1.  Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process.

Authors:  S C Chappel; C Howles
Journal:  Hum Reprod       Date:  1991-10       Impact factor: 6.918

2.  Comparative in vitro and in vivo studies on the biological characteristics of recombinant human follicle-stimulating hormone.

Authors:  B Mannaerts; R de Leeuw; J Geelen; A Van Ravestein; P Van Wezenbeek; A Schuurs; H Kloosterboer
Journal:  Endocrinology       Date:  1991-11       Impact factor: 4.736

3.  Effect of high tonic levels of luteinising hormone on outcome of in-vitro fertilisation.

Authors:  C M Howles; M C Macnamee; R G Edwards; R Goswamy; P C Steptoe
Journal:  Lancet       Date:  1986-08-30       Impact factor: 79.321

4.  Impact of gonadotrophin dose on pre-embryo recovery and development in superovulated mice.

Authors:  S Ziebe; X Guoliang; A G Byskov
Journal:  Hum Reprod       Date:  1993-03       Impact factor: 6.918

5.  Hypophysectomy of the cyclic mouse. II. Effects of follicle-stimulating hormone (FSH) and luteinizing hormone on folliculogenesis, FSH and human chorionic gonadotropin receptors, and steroidogenesis.

Authors:  X N Wang; G S Greenwald
Journal:  Biol Reprod       Date:  1993-03       Impact factor: 4.285

6.  Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone.

Authors:  R Fleming; F Lloyd; M Herbert; J Fenwick; T Griffiths; A Murdoch
Journal:  Hum Reprod       Date:  1998-07       Impact factor: 6.918

7.  Pulsatile secretion of chorionic gonadotropin during the normal menstrual cycle.

Authors:  W D Odell; J Griffin
Journal:  J Clin Endocrinol Metab       Date:  1989-09       Impact factor: 5.958

8.  Hypersecretion of luteinising hormone, infertility, and miscarriage.

Authors:  L Regan; E J Owen; H S Jacobs
Journal:  Lancet       Date:  1990-11-10       Impact factor: 79.321

9.  Heterogeneity of the polycystic ovary syndrome: clinical, endocrine and ultrasound features in 556 patients.

Authors:  G S Conway; J W Honour; H S Jacobs
Journal:  Clin Endocrinol (Oxf)       Date:  1989-04       Impact factor: 3.478

10.  Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients.

Authors:  Z Shoham; A Balen; A Patel; H S Jacobs
Journal:  Fertil Steril       Date:  1991-12       Impact factor: 7.329

View more
  2 in total

1.  GnRH triggering may improve euploidy and live birth rate in hyper-responders: a retrospective cohort study.

Authors:  Justin Tan; Chen Jing; Lisa Zhang; Jasmine Lo; Arohumam Kan; Gary Nakhuda
Journal:  J Assist Reprod Genet       Date:  2020-06-13       Impact factor: 3.412

2.  A randomized, controlled, first-in-patient trial of choriogonadotropin beta added to follitropin delta in women undergoing ovarian stimulation in a long GnRH agonist protocol.

Authors:  Manuel Fernández Sánchez; Hana Višnová; Per Larsson; Claus Yding Andersen; Marco Filicori; Christophe Blockeel; Anja Pinborg; Yacoub Khalaf; Bernadette Mannaerts
Journal:  Hum Reprod       Date:  2022-05-30       Impact factor: 6.353

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.